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Neuromyelitis optica spectrum disorders (NMOSD) are demyelinating, autoimmune diseases affecting
the central nervous system. Typically, recurrent optic neuritis and longitudinal extensive transverse
myelitis dominates the clinical picture. In most cases NMOSD are associated with autoantibodies target-
ing the water channel aquaporin-4 (AQP-4). NMOSD usually present in young adults. Clinical findings
suggestive of NMOSD in elderly patients should raise the suspicion of a paraneoplastic etiology. To our
knowledge, we report the first case of a 66 year-old female patient with paraneoplastic NMOSD that is
associated with squamous cell lung carcinoma. Anti-AQP-4 was present in both the serum and cere-
brospinal fluid of the patient. However, immunhistological staining of the malignant tissue did not show
presence of AQP-4 on the surface of tumour cells.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
Neuromyelitis optica spectrum disorders (NMOSD) are
demyelinating, autoimmune diseases affecting the central nervous
system (CNS). Typically, recurrent optic neuritis and longitudinal
extensive transverse myelitis dominates the clinical picture. In
most cases NMOSD are associated with autoantibodies (IgG) tar-
geting the water channel aquaporin-4 (AQP-4) [1]. AQP-4 is a
transmembrane protein found on the surface of astrocyte projec-
tions constituting to the blood-brain barrier (BBB) and is concerned
with regulating water movement between the cerebrospinal fluid
(CSF), blood and brain [2]. NMOSD usually present in young adults.
Clinical findings suggestive of NMOSD in elderly patients should
raise the suspicion of paraneoplastic aetiology.
To our knowledge, we report the first case of paraneoplastic
NMOSD secondary to squamous cell lung carcinoma. We also
aimed to summarize previously reported cases of paraneoplastic
NMOSD.2. Case report
A 66 year-old female patient presented to the Emergency
Department with complaints of sudden onset left lower extremity
weakness, numbness and reduced sensation that started 3 days
prior to presentation. She was unable to walk on the second day
of her illness. She also complained of sudden onset urinary
incontinence.
She had a history of myelodysplastic syndrome (MDS) with
refractory anaemia for which she received regular blood transfu-
sions every 3–4 weeks. She smoked a pack of cigarette a day. She
denied regular alcohol consumption or illicit drug use.
On admittance she had severe monoparesis (2/5) of the left leg
with diminished reflexes and sensory loss. She had urinary incon-
tinence. Contrast enhanced MRI of the lower thoracic and lumbar
spine showed a long T2 hyperintense lesion extending from 4th
to 10th thoracic vertebrae (Fig. 1). As an additional finding, a neo-
plasm (approximately 20 mm in diameter) in the 6th segment of
the left lung was suspected. A CT guided biopsy of the lesion was
not successful. After consultation with a haematologist, despite
of a possible lung tumour, to treat a suspected funicular myelosis,
parenteral vitamin B12 supplementation was initiated. Over the
next few days, the patient’s condition did not improve. Paresis
and sensory disturbance of the right leg also developed. In the
Fig. 1. MRI of the lower thoracic and lumbar spine showing a long T2 hyperintense
lesion in the thoracic segment of the spinal cord.
Fig. 2. MRI of the cervical and upper thoracic spine showing T2 hyperintense lesion
in the spinal cord below the 7th cervical segment.
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g/l) and white cell count (8 white cells, mostly lymphocytes) were
found. Furthermore, matching oligoclonal bands (OCB) in both the
serum and CSF of the patient were detected. Tests for mycobacte-
ria, CMV, HSV and EBV were negative. The patient’s autoimmune
panel (including ANA, anti-dsDNA, anti-SS-A and SS-B, anti-Scl-
70, anti-Jo-1, anti-RNP-70, anti-RNP/Sm, anti-centromere B) was
normal. The tumour marker, carcinoembryonic antigen (CEA) was
elevated (8.17 ng/ml, normal range <4.70 ng/ml). Bone marrow-
biopsy did not show signs of transformation of MDS to acute mye-
loid leukaemia.
A further worsening of the patient’s condition was detected,
paresis and sensory loss presented on the upper extremities and
trunk. A contrast enhanced MRI of the cervical and upper thoracic
spine found T2 hyperintense lesion in the spinal cord between the
7th cervical and the 10th thoracic segment (Fig. 2).
Later on, the patient complained of blurry vision on both eyes,
more severely affecting the left eye. MRI of the brain showed T2hyperintense lesions in both optic nerves, affecting the left nerve
more profoundly. A repeated lumbar puncture found a protein
level of 0.85 g/l and 15 white cells (dominantly lymphocytes) in
the CSF. Furthermore, Lactobacillus crispatus cultured from the
sample that was thought to be contamination, but antibiotic treat-
ment, ceftriaxone was initiated.
Despite our efforts, the patient’s condition deteriorated further.
In the meantime we repeated the lung biopsy (only a small tissue
sample was obtained), which confirmed a squamous cell carci-
noma. AQP-4 autoantibodies were detected in the serum and in
the CSF. No other autoantibodies (amphiphysin, CV2-CRMP5 [col-
lapsin response mediator-protein-5], Ma2 [Ta], RI [ANNA2], Yo
[PCA1], Hu [ANNA1]) were detected in the serum of the patient.
Based on the patient’s progressing neurological state, MRI findings
(optic neuritis of both optic nerves and long extensive transverse
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sized that the patient had paraneoplastic NMOSD. The patient was
in a severe condition (she had dyspnoea due to muscle weakness),
therefore surgical removal of the tumour or plasmapheresis could
not be performed due to the high mortality risk of these proce-
dures. Intravenous immunoglobulin treatment was given, but no
improvement was detected. Intravenous methylprednisolone had
no beneficial effect either. Unfortunately, the patient died a few
days later and the family did not consent to autopsy. Post-
mortem immunhistological staining of the minute malignant tis-
sue sample did not show presence of AQP-4 on the surface of
tumour cells.3. Discussion
NMOSD most commonly affect young adults (between 35 and
45 years of age) and there is a female predominance [3]. NMOSD
can have a monophasic or relapsing course. The latter is more com-
mon, presenting in approximately 80–90% of the cases. Anti-AQP-4
IgG is detected in the serum of most patients. Anti-AQP-4 has a
specificity of more than 90% and a sensitivity of approximately
70% for NMOSD [4]. AQP-4 is found not only in astrocytic foot pro-
cesses, but in the membrane of skeletal muscle, epithelia of breast
and salivary glands, tracheal and bronchial epithelium, basolateral
membranes of distal collecting tubules, parietal cells of the stom-
ach, and epithelium of the colon [5]. Interestingly, these organs
are rarely affected in anti-AQP-4 seropositive NMOSD cases. Chan
et al. demonstrated that AQP-4 is also present on the surface of
thymoma cells, but not in the membrane of normal thymus tissue
[6]. Furthermore, they showed that anti-AQP-4 taken from serum
of NMOSD patients bound to the receptors expressed by thymoma
cells [6]. These findings could explain the frequent simultaneous
presentation of myasthenia gravis and NMOSD [7,8]. Also, studies
showed that AQP-4 is expressed in breast cancer, low-grade glio-
mas and non-small cell lung cancer (NSCLC) cells even in patients
not showing neurological symptoms [9–11]. AQP-4 might play a
role in adhesion, migration and invasiveness of tumour cells.
NMOSD of paraneoplastic aetiology usually present in older
ages compared to typical NMOSD and are subacute in onset [12].
Clinical signs of NMOSD in elderly patients, especially with a his-
tory of smoking and autoimmune disease or cancer in the previous
history or family, should raise the suspicion of paraneoplastic aeti-
ology. Anti-AQP-4 detection in the serum and/or the CSF of
patients can further direct the attention of clinicians towards para-
neoplastic NMOSD. However, in approximately 10–20% of patients
with clinical signs of NMOSD, anti-AQP-4 is absent in the serum
[13]. There are a few proposed explanations to this finding [14].
(a) The detection methods might not be sensitive enough. (b) The
patients might suffer from multiple sclerosis rather than NMOSD.
(c) Symptoms might not be related to autoimmune lesions in the
CNS. (d) Other antibodies are responsible for CNS damage. It has
been reported that paraneoplastic syndromes of optic neuropathy
and myelitis associated with anti-CV2-CRMP5 (collapsin response
mediator-protein-5), ANNA-1 (antineural nuclear antibody) or
anti- amphyphisin can mimic NMOSD [15]. A few cases have been
reported where anti-CV2/CRMP5 onconeural antibodies were pre-
sent in anti-AQP-4 seronegative patients with symptoms of
NMOSD [16,17]. Other antibodies in seropositive patients included
ANNA-1, acetylcholine receptor-antibody, and N-type calcium
channel (see Table 1 for references, which summarizes previously
reported cases of paraneoplastic NMOSD). It is unknown whether
these antibodies have an actual role in the development of CNS
lesions in NMOSD or are just coincidental findings. Apart from
anti-AQP-4, we could not detect any other autoantibodies in the
serum of our patient.Paraneoplastic neurological syndromes are the consequence of
autoimmune response to neural antigens expressed by tumour
cells [18]. The immune system recognizes antigens found on the
surface of tumour cells which are also present in healthy tissues.
The immune system cannot differentiate between the two and
attacks both. Immunhistological staining of our patient’s tissue
sample taken from the lung tumour did not show AQP-4 on the
surface of malignant cells. However, since the tissue sample was
a very small one, we cannot rule out the possibility of the presence
of AQP-4 in the membrane of tumour cells in other areas of the
neoplasm. We base this hypothesis on the simultaneous presence
of lung squamous cell carcinoma, characteristic symptoms of
NMOSD and anti-AQP-4 antibodies in both the serum and CSF of
the patient. We do not believe that these findings could be
unrelated.
The development of paraneoplastic NMOSD is regulated by both
the innate and adaptive immune system [3]. AQP-4 expressed on
the surface of tumour cells, is possibly recognized as a foreign anti-
gen by the immune system and therefore induces IgG production
(anti-AQP-4) in the periphery. Anti-AQP-4 can access the CNS
through the circumventricular organs [19]. This hypothesis is sup-
ported by the fact that in NMOSD the area postrema and hypotha-
lamus can be affected causing symptoms of nausea, hiccups,
vomiting and diencephalic syndrome. Once in the CNS, anti-AQP-
4 binds to astrocytic foot processes containing AQP-4 to form an
antigen-antibody complex. This leads to internalization and
endolysosomic degradation of AQP-4 [19]. This finding is sup-
ported by pathologic investigations which show reduced AQP-4
expression in CNS lesions of NMOSD patients [20]. The antigen-
antibody complex causes complement activation and antibody
dependent cellular cytotoxicity (ADCC) mediated by granulocytes
and natural killer cells. The activation of the complement cascade
leads to the formation of membrane attack complex and thus com-
plement dependent cytotoxicity (CDC) and recruitment of more
inflammatory cells. The degranulation of leukocytes augments
inflammation in the CNS, disrupting the BBB and therefore initiat-
ing a vicious circle by allowing more anti-AQP-4 to access the CNS.
ADCC and CDC directly cause astrocyte cell death, while it is
believed that demyelination, oligodendroglial and neuronal cell
death are secondary to inflammatory processes [21].
Kitazawa et al. reported a case of an 87 year-old patient who
developed symptoms of NMOSD after the diagnosis of prostate
adenocarcinoma and also after injection of 23-valent pneumococ-
cal vaccination [22]. They hypothesized that the patient was an
asymptomatic anti-AQP-4 carrier, until the prostate tumour
induced CD4 T-lymphocyte activation and INF-c secretion. Accord-
ing to the authors, anti-AQP-4 and T-cell mediated response alto-
gether have resulted in NMOSD. Also, injection of the vaccine
may have caused complement activation and together with the
presence of anti-AQP-4 caused a relapse in the patient’s condition.
This hypothesis is supported by two experiments, which found
that injection of anti-AQP-4 from NMOSD patient into mice alone
did not cause NMOSD-like lesions, only after induction of experi-
mental autoimmune encephalomyelitis (EAE) or co-injection of
human complement [23,24]. Armagan et al. reported a case of
breast carcinoma and possibly paraneoplastic long extensive trans-
verse myelitis (LETM) with anti-AQP-4 seropositivity [9]. Interest-
ingly, they also reported 3 other cases of the same type of breast
carcinoma with anti-AQP-4 in the patients’ serum; however, they
did not develop neurological symptoms. These findings indicate
that the presence of anti-AQP-4 in the serum alone is not enough
for the development of NMOSD. Antibody induced T-cell activation
and/or complement activation is also required. It is yet to be eluci-
dated why anti-AQP-4 causes NMOSD symptoms in some individ-
uals, and why it can be a coincidental finding in symptomless
patients. It is possible that the presence of anti-AQP-4 needs a
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to profound lesions in the CNS and causing the symptoms of
NMOSD.
4. Conclusion
NMOSD in elderly patients are infrequent findings that should
always raise the suspicion of a paraneoplastic aetiology and war-
rants thorough investigations in search for an underlying cancer.
Risk factors include smoking, previous cancer or autoimmune dis-
ease in the patient’s history and/or in the patient’s family history.
Treatment options comprise of oncologic therapy to eradicate the
tumour and also immunosuppressive therapy (intravenous ster-
oids, plasmapheresis, intravenous immunoglobulin, azathioprine
or rituximab). The sooner the treatment is initiated, the better
the prognosis for the patient, therefore early diagnosis of paraneo-
plastic NMOSD is imperative for better outcome. It is also impor-
tant to note, that the presence of anti-AQP-4 is not a necessity in
the diagnosis of paraneoplastic NMOSD. Autoimmune reactions
to other onconeural antigens, including CV2/CRMP5, ANNA-1 and
amphyphisin can also cause symptoms of NMOSD.
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